Related Experiment Videos
Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA)
1Department of Biochemistry and Molecular Biology, University of Southern California School of Medicine, Los Angeles, California 90033, USA.
Abstract:
A new provirus clone of feline leukemia virus (FeLV), which we named FeLV-A (Rickard) or FRA, was characterized with respect to viral interference group, host range, complete genome sequence, and in vivo pathogenicity in specific-pathogen-free newborn cats. The in vitro studies indicated the virus to be an ecotropic subgroup A FeLV with 98% nucleotide sequence homology to another FeLV-A clone (F6A/61E), which had also been fully sequenced previously. Since subgroup B polytropic FeLVs (FeLV-B) are known to arise via recombination between ecotropic FeLV-A and endogenous FeLV (enFeLV) env elements, the in vivo studies were conducted by direct intradermal inoculation of the FRA plasmid DNA so as to eliminate the possibility of coinoculation of any FeLV-B which may be present in the inoculum prepared by propagating FeLV-A in feline cell cultures. The following observations were made from the in vivo experiments: (i) subgroup conversion from FeLV-A to FeLV-A and FeLV-B, as determined by the interference assay, appeared to occur in plasma between 10 and 16 weeks postinoculation (p.i.); (ii) FeLV-B-like recombinants (rFeLVs), however, could be detected in DNA isolated from buffy coats and bone marrow by PCR as early as 1 to 2 weeks p.i.; (iii) while a mixture of rFeLV species containing various amounts of N-terminal substitution of the endogenous FeLV-derived env sequences were detected at 8 weeks p.i., rFeLV species harboring relatively greater amounts of such substitution appeared to predominate at later infection time points; (iv) the deduced amino acid sequence of rFeLV clones manifested striking similarity to natural FeLV-B isolates, within the mid-SU region of the env sequenced in this work; and (v) four of the five cats, which were kept for determination of tumor incidence, developed thymic lymphosarcomas within 28 to 55 weeks p.i., with all tumor DNAs harboring both FeLV-A and rFeLV proviruses. These results provide direct evidence for how FeLV-B species evolve in vivo from FeLV-A and present a new experimental approach for efficient induction of thymic tumors in cats, which should be useful for the study of retroviral lymphomagenesis in this outbred species.
Insights
This study shows how feline leukemia virus subgroup B (FeLV-B) evolves from FeLV-A in cats. Researchers used a new FeLV-A clone to demonstrate FeLV-B emergence and induce thymic tumors, aiding retroviral lymphomagenesis research.
Area of Science:
- Virology
- Oncology
- Molecular Biology
Background:
- Feline leukemia virus (FeLV) causes disease in cats.
- Subgroup B polytropic FeLVs (FeLV-B) are thought to arise from recombination between ecotropic FeLV-A and endogenous FeLV (enFeLV) env elements.
- Understanding FeLV-B evolution is crucial for feline retroviral research.
Purpose of the Study:
- To characterize a new feline leukemia virus subgroup A (FeLV-A) provirus clone, FRA.
- To investigate the in vivo pathogenicity and evolution of FeLV-A to FeLV-B.
- To establish an experimental model for studying retroviral lymphomagenesis.
Main Methods:
- Characterization of FeLV-A (Rickard) or FRA, including genome sequencing and host range analysis.
- In vivo studies involving intradermal inoculation of FRA plasmid DNA into specific-pathogen-free newborn cats.
- Detection of viral subgroup conversion and recombinant FeLVs (rFeLVs) using interference assays and PCR.
- Analysis of env gene sequences and tumor incidence in inoculated cats.
Main Results:
- FeLV-A subgroup conversion to FeLV-A and FeLV-B occurred in plasma 10-16 weeks post-inoculation.
- FeLV-B-like recombinants (rFeLVs) were detected in DNA from buffy coats and bone marrow as early as 1-2 weeks post-inoculation.
- Four out of five cats developed thymic lymphosarcomas, with tumor DNA containing both FeLV-A and rFeLV proviruses.
Conclusions:
- Direct evidence was provided for the in vivo evolution of FeLV-B from FeLV-A.
- A novel experimental approach for inducing thymic tumors in cats was established.
- This model is valuable for studying retroviral lymphomagenesis in an outbred species.